Cargando…

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study

BACKGROUND: Cachexia, a disorder associated with anorexia, inflammation, and muscle wasting, is frequent in cancer patients. We performed post‐hoc analyses of the ONO‐7643‐04 study to investigate the efficacy and safety of anamorelin in subgroups of Japanese patients with non‐small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takayama, Koichi, Takiguchi, Toru, Komura, Naoyuki, Naito, Tateaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939183/ https://www.ncbi.nlm.nih.gov/pubmed/36394148 http://dx.doi.org/10.1002/cam4.5206

Ejemplares similares

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia
por: Hamauchi, Satoshi, et al.
Publicado: (2019)

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
por: Katakami, Nobuyuki, et al.
Publicado: (2017)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
por: Naito, Tateaki, et al.
Publicado: (2022)

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
por: Takayama, Koichi, et al.
Publicado: (2016)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023)

The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis
por: Taniguchi, Jumpei, et al.
Publicado: (2023)

Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)

Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
por: Graf, Solomon A, et al.
Publicado: (2017)

Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia
por: Naito, Tateaki
Publicado: (2019)

Nursing Management of Cancer Cachexia: A New Frontier
por: Naito, Tateaki
Publicado: (2021)

Challenges in enhancing physical performance in thoracic cancer cachexia
por: Naito, Tateaki
Publicado: (2021)

Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017)

Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review
por: Naito, Tateaki
Publicado: (2019)

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
por: Currow, D., et al.
Publicado: (2017)

Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review
por: Sato, Rika, et al.
Publicado: (2021)

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
por: Pietra, Claudio, et al.
Publicado: (2014)

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
por: Oshima, Yuri, et al.
Publicado: (2022)

Efficacy and safety of guanfacine extended‐release in Japanese adults with attention‐deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double‐blind, placebo‐controlled study
por: Naya, Noriyuki, et al.
Publicado: (2020)

Refractory Monomorphic Ventricular Tachycardia Induced by Anamorelin
por: Sakagami, Hiroaki, et al.
Publicado: (2022)

Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses
por: Coghill, David R., et al.
Publicado: (2020)

Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials
por: Micca, Joseph L, et al.
Publicado: (2013)

Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion
por: Currow, David C., et al.
Publicado: (2018)

Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol
por: Hoon, Siao Nge, et al.
Publicado: (2020)

The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
por: Wakabayashi, Hidetaka, et al.
Publicado: (2020)

Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS‐ADONIS trials
por: Thind, Munveer, et al.
Publicado: (2022)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
por: Garcia, Jose M, et al.
Publicado: (2014)

Appetite and food intake results from phase I studies of anamorelin
por: Blum, Robert A., et al.
Publicado: (2019)

An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin
por: Leese, Philip T, et al.
Publicado: (2015)

Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses
por: Iqbal, Ahmar, et al.
Publicado: (2015)

Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial
por: Anders, Hans-Joachim, et al.
Publicado: (2023)

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan
por: Watanabe, Yoshinori, et al.
Publicado: (2018)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

Impact of Cancer Cachexia on Hospitalization-associated Physical Inactivity in Elderly Patients with Advanced Non-small-cell Lung Cancer
por: Morikawa, Ayumu, et al.
Publicado: (2018)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Challenges and Solutions to Pre- and Post-Randomization Subgroup Analyses
por: Desai, Manisha, et al.
Publicado: (2014)

Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials
por: Yood, Robert A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m1plfd5ppfmh9rjjh0a33q7mko